Ligand Pharmaceuticals (LGND) said Thursday it agreed to provide up to $47 million to AvenCell Therapeutics to support development of its cell therapy programs.
Ligand said it will provide up to $41 million in exchange for a mid-single-digit to low-double-digit royalty on worldwide annual net sales of AvenCell's current and future pipeline.
The funding will be provided in four tranches, with later payments tied to clinical milestones and other conditions, it added.
Ligand said it also committed up to $6 million to AvenCell's Series C financing.
AvenCell is developing therapies in a phase 1 trial to treat cancers, Ligand added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments